Evidence map›Paper›PMID 20815926›Full record

ArticleBMC pharmacology2010

Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia.

Che-Chuan Wang, Chung-Ching Chio, Ching-Hong Chang, Jinn-Rung Kuo, Ching-Ping Chang

Open access · hybridAbstract read
In one paragraph

Article in BMC pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Agmatine-IRF2BP2 interaction induces M2 phenotype of microglia by increasing IRF2-KLF4 signaling.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Effectiveness of arginase inhibitors against experimentally induced stroke.Naunyn-Schmiedeberg's archives of pharmacology · 2018
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Che-Chuan Wang *Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
Chung-Ching Chio *Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
Ching-Hong ChangDepartment of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
Jinn-Rung KuoDepartment of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
Ching-Ping ChangDepartment of Biotechnology, Southern Taiwan University, Tainan 710, Taiwan.
Chi Mei Medical Center · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough agmatine therapy in a mouse model of transient focal cerebral ischemia is highly protective against neurological injury, the mechanisms underlying the protective effects of agmatine are not fully elucidated. This study aimed to investigate the effects of agmatine on brain apoptosis, astrogliosis and edema in the rats with transient cerebral ischemia.

methodsFollowing surgical induction of middle cerebral artery occlusion (MCAO) for 90 min, agmatine (100 mg/kg, i.p.) was injected 5 min after beginning of reperfusion and again once daily for the next 3 post-operative days. Four days after reperfusion, both motor and proprioception functions were assessed and then all rats were sacrificed for determination of brain infarct volume (2, 3, 5-triphenyltetrazolium chloride staining), apoptosis (TUNEL staining), edema (both cerebral water content and amounts of aquaporin-4 positive cells), gliosis (glial fibrillary acidic protein [GFAP]-positive cells), and neurotoxicity (inducible nitric oxide synthase [iNOS] expression).

resultsThe results showed that agmatine treatment was found to accelerate recovery of motor (from 55 degrees to 62 degrees) and proprioception (from 54% maximal possible effect to 10% maximal possible effect) deficits and to prevent brain infarction (from 370 mm3 to 50 mm3), gliosis (from 80 GFAP-positive cells to 30 GFAP-positive cells), edema (cerebral water contents decreased from 82.5% to 79.4%; AQP4 positive cells decreased from 140 to 84 per section), apoptosis (neuronal apoptotic cells decreased from 100 to 20 per section), and neurotoxicity (iNOS expression cells decreased from 64 to 7 per section) during MCAO ischemic injury in rats.

conclusionsThe data suggest that agmatine may improve outcomes of transient cerebral ischemia in rats by reducing brain apoptosis, astrogliosis and edema.

Indexed as

AgmatineAnimalsApoptosisAquaporin 4AstrocytesBiomarkersBrainBrain EdemaGlial Fibrillary Acidic ProteinGliosisInfarction, Middle Cerebral ArteryIschemic Attack, TransientMaleMovement DisordersNeuronsNeuroprotective AgentsAgmatineAqp4 protein, ratAquaporin 4BiomarkersGlial Fibrillary Acidic ProteinNeuroprotective AgentsNitric Oxide Synthase Type IINos2 protein, rat

Identifiers

PMID20815926
PMCPMC2941483
OpenAlexW2108175051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.